Candriam SCA’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Candriam SCA’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,922	Closed	-$420K	–	902
2023 Q1	$420K	Sell	18,922 -78,587	-81%	-$986K	﹤0.01%	809
2022 Q4	$1.03M	Sell	97,509 -110,142	-53%	-$889K	0.01%	692
2022 Q3	$934K	Buy	+207,651	New	+$946K	0.01%	725

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Candriam SCA's PRVB Position: Q2 2023 in Review

Candriam SCA sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 18,922 shares — an estimated $420K sold.

Candriam SCA first reported a position in PRVB in Q3 2022 and held it in 3 quarters. The position peaked at $1.03M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Candriam SCA reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 18,922 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $420K.
Candriam SCA first reported a position in Provention Bio, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Candriam SCA's Provention Bio, Inc. Common Stock position peaked at $1.03M in Q4 2022.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.